
The Implications of New Research Findings for the Management of Endometrial Cancer
Oncology Today with Dr Neil Love
00:00
The Response Rates of Single Agent IO in MSI High Patients
The MSI high patient seems to do markedly better than those with a somatic or germline mutation. We don't see an arm like that in these two trials, so what are your thoughts about that? It looks like the response rates of single agent IO. I'm not sure why there wasn't a trial looking at this, but they look pretty substantial. How do you think about treating first line therapy than curable metastatic disease? Yeah, it's a great question. There are large studies. It's going to take a while. And we have some theoretic reasons to think triplet therapy is important.
Transcript
Play full episode